...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial

Just another failure!!,,,18 more to come possibly????,,,,,hahhahahaha...if these guys didnt have bad luck they would have no luck as is said!!!,,,we are so used to these results it doesnt even trigger heart fluctuations in me anymore!!,,

Share
New Message
Please login to post a reply